Mark Kirschbaum
2021
In 2021, Mark Kirschbaum earned a total compensation of $794.6K as Senior Vice President and Chief Medical Officer at Cyclacel Pharmaceuticals, a 75% increase compared to previous year.
Compensation breakdown
| Bonus | $140,000 |
|---|---|
| Option Awards | $263,000 |
| Salary | $350,000 |
| Other | $41,576 |
| Total | $794,576 |
Kirschbaum received $350K in salary, accounting for 44% of the total pay in 2021.
Kirschbaum also received $140K in bonus, $263K in option awards and $41.6K in other compensation.
Rankings
In 2021, Mark Kirschbaum's compensation ranked 9,493rd out of 12,406 executives tracked by ExecPay. In other words, Kirschbaum earned more than 23.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,493 out of 12,406 | 24th |
Division Manufacturing | 4,206 out of 5,492 | 23rd |
Major group Chemicals And Allied Products | 1,864 out of 2,368 | 21st |
Industry group Drugs | 1,653 out of 2,089 | 21st |
Industry Pharmaceutical Preparations | 1,228 out of 1,536 | 20th |
Source: SEC filing on April 26, 2022.
Kirschbaum's colleagues
We found two more compensation records of executives who worked with Mark Kirschbaum at Cyclacel Pharmaceuticals in 2021.
News
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2023 pay slips 13% to $661K
May 7, 2024
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2022 pay falls 43% to $764K
April 28, 2023
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2021 pay slips 5% to $1.3M
April 26, 2022
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2020 pay jumps 39% to $1.4M
April 29, 2021